Apoptosis induced by satraplatin in human ovarian carcinoma cells A2780

Abstract

Abstract: AIM: To observe the growthinhibiting cell cycle-modifying and apoptosis-inducing effects of satraplatin on human ovarian carcinoma cell line A2780, and to explore its possible mechanism. METHODS: The effect of satraplatin on A2780 cells proliferation was determined using MTT, and the change in cell cycle was analyzed using PI staining.Morphologic change was visualized by fluorescence and electron microscopy. AnnexinV-FITC PI staining multiparameter flow cytometry and immuno-histochemical TUNEL assay were used to detect apoptotic cells.The activity of caspase-3 and the effect of pan-caspase inhibitor on cell viability were measured as well. RESULTS: The growthinhibiting and apoptosis-inducing effects of satraplatin were dose-dependent and similar to those of cisplatin.Satraplatin mainly caused A2780 cell accumulation in S phase accompanied by minor accumulation in G₂/M phase.Cells treated with satraplatin exhibited typical morphology of apoptosis.Satraplatin-induced increase in caspase-3 activity of A2780 cells was concentration-dependent.The viability of A2780 cells was affected by pan-caspase inhibitor z-VAD-fmk in a dose-dependent manner under certain concentration of z-VAD-fmk. CONCLUSION: Satraplatin-induced apoptosis in A2780 in vitro was observed.Caspase-dependent and independent pathways were involved in apoptosis induced by satraplatin, and the latter included caspase-3 dependent and non-caspase-3 dependent pathways.

Key words: ovarian carcinoma, satraplatin, cisplatin, apoptosis, caspase

CLC Number:

R965.2
R966

YAN Dong-mei, TU Ling-lan, PENG Xiao-ying, LI Wen-jun, SHEN Zheng-rong. Apoptosis induced by satraplatin in human ovarian carcinoma cells A2780[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 869-876.

References

1 Kelland LR.An update on satraplatin:the first orally available platinum anticancer drug [J].Expert Opin Investing Drugs, 2000;9:1373-1382.
2 Kelland LR, Abel G, McKeageMJ, et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV):an orally active platinum drug[J].Cancer Res, 1993;53:2581-2586.
3 Giandomenico CM, AbramsMJ, Murrer BA, et al.Carboxylation of kinetically Inert platinum (IV) hydroxy complexes.An entree into orally active platinum (IV) antitumor agents[J].Inorg Chem, 1995;34:1015-1021.
4 Yan DM, Li WJ, Peng XY.Recent advances of platinum-containing anticancer drugs[J].China Pharmacy, 2005;16:1022-1025.
5 Li WJ, Ma ZY.Satraplatin:new-generation platinum antitumor agent[J].Chin J Mod Appl Pharmacy, 2004;21:25-27.
6 Mckeagf MJ.New-generation platinum drugs in the treatment of cisplatin-resistant cancers [J].Expert Opin Investig Drugs, 2005;14:1033-1046.
7 Li WJ, Peng XY, Ma ZY, Zheng YX.The preclinical antitumor study of satraplatin[J].Chin New Drug J, 2003;12:643-645.
8 Sternberg CN, Whelan P, Hetherington J, et al.Genitourinary Tract Group of the EORTC.Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs.Prednisone alone in Patients with Hormone-Refractory Prostate Cancer[J].Oncology, 2005; 68:2-9.
9 Latif T, Wood L, Connell C, et al.Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)[J].Invest New Drugs, 2005;23:79-84.
10 Zaffaroni N, Silvestrini R, Orlandi L, et al.Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and-resistant human ovarian cells [J].Br J Cancer, 1998;77:1378-1385.
11 Faivre S, Chan D, Salinas R, et al.DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells[J].Biochem Pharmacol, 2003;66:225-237.
12 Cummings BS, Schnellmann RG.Cisplatin-induced renal cell apoptosis:caspase-3-dependent and-independent pathways[J]. J Pharmacol Exp Ther, 2002;302:8-17.
13 Kim JS, Lee JM, Chwae YJ, et al.Cisplatin-induced apoptosis in Hep3B cells:mitochondria-dependent and-independent pathways[J].Biochem Pharmacol, 2004;67:1459-1468.
14 OrmerodMG, O'Neill C, Rovertson D, et al.Cis-diamminedichloroplatinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines[J]. Cancer Chemother Pharmacol, 1996;37:463-471.
15 O'Neill CF, Ormerod MG, Robertson D, et al.Apoptotic and non apoptotic cell death induced by cis and trans analogues of a novel ammine (cy clohexylamine) dihydroxodichloroplatinum (IV) complex[J].Br J Cancer, 1996;74:1037-1045.
16 O'Neill CF, Koberle B, Masters JRW, et al.Gene-specific repair of Pt DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin[J].Br J Cancer, 1999; 81:1294-1303.
17 Ormerod MG, Orr RM, Peacock JH.The role of apoptosis in cell killing by cisplatin:a flow cytometric study[J].Br J Cancer, 1994;69:93-100.
18 Sorenson CM, Eastman A.Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity:role of G2 arrest and DNA double-strand breaks[J].Cancer Res, 1988;48:4484-4488.
19 Sorenson CM, Eastman A.Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells[J].Cancer Res, 1988;48:6703-6707.
20 Vaisman A, Varchenko M, Said I, et al.Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity[J].Cytometry, 1997;27:54-64.
21 Cohen GM.Caspase:The executioners of apoptosis [J].Biochem J, 1997;326:1-16.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	WANG Xinyu, CHEN Yipeng, MA Yongli, HE Junfei. Study of the improvement effect of "DuZhong-DangGui" on osteoarthritis rats via regulating NLPR3 inflammasome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 751-757.
[3]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[4]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[5]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[6]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[7]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[8]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[9]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[10]	LI Xueheng, LI Long. Research progress on the relationship between melatonin and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 715-720.
[11]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[12]	YANG Liu, LUO Ailin, LI Shiyong. Advance of general anesthetics-induced developing brain injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1381-1390.
[13]	TAN Fenglang, REN Hongli, WANG Hongfei. Effect of Phellodendri amurense extract on hippocampal nerve cells induced by Aβ_1-42 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1213-1220.
[14]	PAN Rongrong, ZHI Yinghao, JIN Yongxi, ZHOU Xiahui. Influences of theaflavins on neuronal apoptosis and blood-brain barrier in rats with cerebral hemorrhage by regulating CaMKK2/AMPK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1240-1246.
[15]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.